西格列汀联合厄贝沙坦治疗早期糖尿病肾病疗效观察  

Efficacy of Sitagliptin Combined with Irbesartan in the Treatment of Early Diabetic Nephropathy

作　　者：陈海静[1] 孙海燕[1] 刘红丹[1] 

机构地区：[1]北京市房山区第一医院内分泌科,北京102400

出　　处：《中国药师》2017年第8期1433-1435,共3页China Pharmacist

摘　　要：目的:观察西格列汀联合厄贝沙坦治疗早期糖尿病肾病的疗效及安全性。方法:初次诊断为糖尿病肾病的患者49例随机分为观察组25例和对照组24例。在糖尿病饮食、健康教育及规范降糖药物治疗基础上,对照组给予厄贝沙坦片150 mg,po,qd;观察组在对照组基础上再加用西格列汀片100 mg,po,qd。均维持治疗3个月。比较两组患者治疗前后空腹血糖(FBG)、餐后血糖(PBG)、糖化血红蛋白(Hb A1c),收缩压(SBP)、舒张压(DBP),尿微量白蛋白(m Alb)、体质指数(BMI)等指标变化,以及低血糖发生情况。结果:观察组患者治疗后FBG、PBG、Hb A1c、SBP、DBP、m Alb均较治疗前显著降低(P<0.05)。对照组治疗后FBG、PBG、Hb A1c无明显变化(P>0.05),SBP、DBP、m Alb有明显下降(P<0.05)。治疗后观察组FBG、PBG、Hb A1c、m Alb均显著低于对照组患者(P<0.05),两组间SBP、DBP比较差异无统计学意义(P>0.05)。治疗前后两组患者BMI无明显变化(P>0.05)。观察组发生低血糖1例,与对照组发生率比较,差异无统计学意义(P>0.05)。结论:西格列汀联合厄贝沙坦治疗早期糖尿病肾病,能有效降低患者血糖,减少m Alb排泄,延缓肾病进展。Objective： To observe the clinical efficacy and safety of the combination therapy of sitagliptin and irbesartan in the treat- ment of early diabetic nephropathy. Methods： Totally 49 cases of initial diagnosed diabetic nephropathy were randomly divided into the observation group （25 cases） and the control group （24 cases）. On the basis of diabetic diet, health education and regular hypoglycemic drugs, the control group was treated with irbesartan tablets, 150 mg, po, qd, and on the basis of the control group, the observation group was treated with sitagliptin tablets 100mg, po, qd. All the patients were treated for 3 months. The fasting blood glucose （FBG）, post- prandial blood glucose （ PBG ）, glycosylated hemoglobin （ HbA1 c）, systolic blood pressure （SBP）, diastolic blood pressure （DBP）, uri- nary microalbumin （mAlb） and body massindex（BMI） were compared between the groups before and after the treatment. Results： After the treatment, FBG, PBG, HbA1 c, SBP, DBP and mAlb in the observation group were significantly lower than those before the treatment （P 〈 0. 05）. Hypoglycemia occntrredin in one patient in the observation group. There were no significant changes in FBG, PBG and HbAlc in the control group （P 〉 0.05 ）, and SBP, DBP and mAlb decreased significantly （P 〈0.05）. After the treatment, the decrease of FBG, PBG, HbAle and mAlb in the observation group was more significant than that in the control group, and the difference was sta- tistically significant （P 〈 O. 05）. The decrease of blood pressure between the groups was not statistically signiiieant （ P 〉 0.05 ）. Hypo- glycemia oeenrredin in one patient in the observation group. There was. no significant difference in BMI between the groups and before and after the treatment （ P 〉0. 05）. There was no significant difference in the incidence of hypoglycemia＇between the groups after the treat- ment （ P 〉 0.05 ）. Conclusion： The combination of sitagliptin and irbesartan in t

关 键 词：糖尿病肾病 磷酸西格列汀 厄贝沙坦 尿微量白蛋白 

分 类 号：R977.15[医药卫生—药品]